Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America.
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Why Lilly (LLY) International Revenue Trends Deserve Your Attention
Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
3 No-Brainer Stocks to Buy in May
Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the summer.
Eli Lilly's Meltdown Triggers Near Doubling Upside Potential - Reiterate Buy
LLY's valuation remains highly attractive post-market overreaction, with the FY2025 bottom-line impact merely attributed to one-time acquired IPR&D expenses from ongoing M&A activities. Despite the tariff/ competition headwinds, its strategic capex investments within the US and intensified R&D efforts bolster its competitive advantage and growth prospects. While LLY's balance sheet may have temporarily deteriorated, we are not overly concerned, given the richer cash flow generation and stable leverage ratio thus far.
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations Dave Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Anne White - President of Lilly Neuroscience Ilya Yuffa - President of Lilly International Jake Van Naarden - President of Lilly Oncology Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference Call Participants Asad Haider - Goldman Sachs Geoff Meacham - Citibank Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Alex Hammond - Wolfe Seamus Fernandez - Guggenheim Tim Anderson - Bank of America Evan Seigerman - BMO Capital Markets James Shin - Deutsche Bank Umer Raffat - Evercore Steve Scala - TD Cowen Courtney Breen - Bernstein David Risinger - Leerink Partners Kerry Holford - Berenberg Akash Tewari - Jefferies Trung Huynh - UBS Carter Gould - Cantor Rajesh Kumar - HSBC Kripa Devarakonda - Truist Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates.
